Valeant Pharmaceuticals International (VRX)

Pershing Square · 2015-10

arc beats above · slides in the middle · loops below · scroll → 0 LOOPS

Deck intelligence map

coverage by narrative range · generated from this deck JSON

Narrative range 39 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Whole deck 39 slides 15.4% 6/39 slides 15.4% 6/39 slides · 31 hits

— 0/39 slides

12.8% 5/39 slides · 6 hits

— 0/39 slides

Slide inventory

every slide · same image gating as the playbook

Open slide detail

Right-hand portion of the chart (Sep-Oct 2015, showing sharp price decline) is grayed out with a 'See next page' label, deferring that period to a follow-up sliestablish_context

Open slide detail

The slide uses a list format to build a case for regulatory scrutiny.expose_contradiction

Open slide detail

The slide uses color-coding to distinguish between Valeant and Philidor entities, with a focus on the timeline of their business relationship.expose_contradiction

Open slide detail

This slide is designed to defend Pershing Square against potential accusations of complicity or prior knowledge regarding Valeant's controversial Philidor acquipreempt_rebuttal

Open slide detail

summarize

Open slide detail

The slide uses a simple callout box to set up a comparison with a past corporate scandal.cite_precedent

Open slide detail